50 results about "Predictive marker" patented technology

The invention belongs to the field of biomedicine, and particularly relates to application of CRYL1 protein in preparation of a product for evaluation, diagnosis or auxiliary diagnosis of postoperative recurrence risk of calcium oxalate kidney stone combined with renal nipple calcium spot, and the sequence of the CRYL1 protein is shown as SEQ ID NO.1. The invention discovers that the expression of the CRYL1 protein in renal tubules and collecting tube cells of renal papillary calcium spot tissues is reduced for the first time, and tests prove that the urine CRYL1 protein is a predictive factor and a predictive marker for postoperative recurrence of a patient with CaOx kidney stone combined with renal papillary calcium spot. The CRYL1 protein detection kit is further researched and developed to be used for detecting or evaluating the postoperative recurrence risk of patients suffering from CaOx kidney stone combined with renal nipple calcium spots, personalized follow-up visit and prevention schemes of the patients are promoted, and the CRYL1 protein detection kit has huge clinical application prospects.

The invention discloses intestinal bacteria and serum metabolites which can be used as biomarkers of type 2 diabetes mellitus (prediabetes mellitus (PDM), new diagnosis diabetes mellitus (NDDM) and diabetes mellitus (P2DM) after medication) in different disease stages, and application of the intestinal bacteria and the serum metabolites. Aiming at type 2 diabetes mellitus, predictive markers including staphylococcus aureus, escherichia coli, klebsiella pneumoniae, branched chain amino acids (leucine, valine and isoleucine) and the like, especially staphylococcus aureus of which the genome contains acetolactate synthase (ALS), are efficiently screened out. The type 2 diabetes mellitus marker disclosed by the invention can be used for early warning the illness risk of type 2 diabetes mellitus and guiding the adjustment of an intestinal microbial environment; the method can be used for indicating the correlation between the intestinal microbial environment and the type 2 diabetes mellitus and is used for assisting diagnosis; and drug action target research, accurate medication, pathogenesis research and the like are realized.

The invention discloses a prediction marker and a prediction method for acute upper respiratory infection susceptibility. The prediction marker and the prediction method are used for solving the problem that current acute upper respiratory infection susceptibility risk prediction is low in accuracy. The method comprises the following steps: firstly, providing a prediction marker for acute upper respiratory infection susceptibility, wherein the prediction marker is a prediction feature combination obtained by comprehensively considering human health state blood routine data and baseline blood transcriptome data and carrying out feature processing; secondly, providing a prediction method, and obtaining a to-be-detected blood sample; and performing blood analysis based on a to-be-detected blood sample, inputting the obtained blood routine sample and the gene expression sample into a susceptibility prediction model pre-trained based on a prediction marker for susceptibility risk judgment, and obtaining a susceptibility risk assessment result of acute upper respiratory infection of a human body corresponding to the to-be-detected blood sample in a future period of time, therefore, the acute upper respiratory infection susceptibility risk of the human body in a period of time in the future can be simply, quickly and accurately predicted.

The present disclosure provides a method and a gene detection panel for evaluating treatment response, recurrence and survival by detecting genetic variants and their changes before and after concurrent chemoradiotherapy in tumor tissues of patients with esophageal cancer. The present disclosure develops a set of esophageal cancer NGS analysis panel. Aiming at 402 mutation sites including 35 genes that frequently occur in esophageal squamous cell carcinoma tissue cells, 62 pairs of esophageal squamous cell carcinoma tissues before and after CCRT are analyzed for specific site variation, hoping to find new predictive markers. The present disclosure combines these potential markers into an esophageal cancer detection panel, which has extremely high value for improving the prognosis of esophageal cancer.

The objective of the present invention is to provide a disease onset risk prediction device for predicting the onset risk of liver disease from disease-related information about a subject of prediction.　A disease onset risk prediction device according to the present invention includes an information acquisition unit, a prediction unit, and an output unit, wherein: the information acquisition unit acquires disease-related information about a subject of prediction, the disease being liver disease, and the disease-related information including at least one among information acquired by health diagnosis and information acquired by the subject of prediction; the prediction unit predicts a disease onset risk of the subject of prediction from the disease-related information; and the output unit outputs the disease onset risk.

The invention discloses an eccDNAcircATP6V0A1 serving as a predictive marker of cis-platinum drug resistance of hypopharyngeal cancer and an application of the eccDNAcircATP6V0A1. The nucleotide sequence of the predictive marker eccDNA is as shown in SEQ ID NO. 3. According to the invention, a hypopharyngeal carcinoma cisplatin drug-resistant cell line model FaDu / DDP is cultured for the first time, meanwhile, a differential eccDNA expression profile and a circRNA expression profile in hypopharyngeal carcinoma cells FaDu and hypopharyngeal carcinoma cisplatin drug-resistant cells FaDu / DDP are disclosed and analyzed in a combined manner, and the eccDNA circATP6V0A1 is further screened and verified as a predictive marker of hypopharyngeal carcinoma cisplatin drug resistance through combined analysis. And a new treatment strategy diagnosis and treatment thought is provided for cis-platinum chemotherapy of hypopharyngeal carcinoma patients clinically.

The invention relates to application of plasma IL-1Ra as a biomarker in prognosis of sepsis in children. The prognosis product is used for measuring the IL-1Ra level on the first day after sepsis diagnosis, and is used for evaluating the immune state and prognosis of sepsis patients. The invention discloses the potential of IL-1Ra as a sepsis immune response regulatory factor, and the increased level of IL-1Ra can be used as a predictive marker for clinical outcome of sepsis, and especially has important clinical significance in children with abnormal immune function. The discovery provides a new biomarker for early diagnosis, prognosis evaluation and treatment of sepsis, and provides an important basis for clinical management.

A veterinary composition comprising a therapeutically effective amount of a zeolite and at least one member of the Lactobacilli genus, and at least one veterinary acceptable excipient is provided. The

The invention discloses a PCI postoperative MACE risk prediction marker for an acute ST segment elevation type myocardial infarction patient, and belongs to the field of biological medicine. The application comprises application of a reagent for detecting the lipid metabolism marker in preparation of a kit for predicting the risk of main adverse cardiovascular events after the PCI operation of a patient suffering from the acute ST segment elevation type myocardial infarction, and the reagent for detecting the lipid metabolism marker comprises glycodeoxycholic acid, [(2R)-3-[(6Z, 9Z, 12Z)-octadeca-6, 9, 10-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, the detection reagent is selected from one or more of a detection reagent for N-((2S, 3R)-1, 3-dihydroxy octadecane-4-alkene-2-yl) acetamide, a detection reagent for 2-(2, 6, 7, 12-trienoyl) oxy-2-[(Z)-octadecane-9-enoyl] oxypropyl] 2-(trimethyl ammonium) ethyl phosphate, 8-hydroxy-8-(3-octyl oxirane-2-yl) octanoic acid and N-((2S, 3R)-1, 3-dihydroxy octadecane-4-alkene-2-yl) acetamide. The four lipid metabolism markers (C44H80NO8P, C18H34O4, C20H39NO3 and C26H43NO5) screened by the invention are used for the prediction efficiency of MACE prediction, the sensitivity of the four lipid metabolism markers reaches 0.889, the specificity of the four lipid metabolism markers is 0.894, the AUC of the four lipid metabolism markers is 0.921, and the four lipid metabolism markers have high sensitivity and high specificity.

The purpose of the present disclosure is to provide a disease onset risk prediction device for predicting the risk of onset of a renal disease on the basis of disease-related information of a prediction subject.　This disease onset risk prediction device includes an information acquisition unit, a prediction unit, and an output unit. The information acquisition unit acquires disease-related information of a prediction subject, the disease being a renal disease. The disease-related information includes at least one of information acquired by a health diagnosis and information acquired by the prediction subject. The prediction unit predicts a disease onset risk of the prediction subject from the disease-related information, and the output unit outputs the disease onset risk.

The invention discloses application of Keratin5 low expression and PADI3 nuclear translocation in serving as a predictive marker for invasion and metastasis of head and neck squamous cell carcinoma, belongs to the technical field of biological medicine, verifies clinical applicability of KRT5 low expression and / PADI3 nuclear translocation (namely KRT5low / PADI3nucle) serving as a predictive index so as to fill the blank of the prior art, and provides a novel predictive marker for invasion and metastasis of head and neck squamous cell carcinoma. A novel molecular marker and an intervention target spot are provided for precise diagnosis and treatment of the head and neck squamous cell carcinoma; the KRT5 and PADI3 co-expression region forms a specific micro-domain difference and a specific mode in tumor tissues, can be used as an effective head and neck squamous cell carcinoma metastasis prediction marker, and has important scientific significance and application value for optimizing clinical diagnosis and treatment strategies.

The purpose of the present invention is to provide a disease onset risk prediction device for predicting the risk of onset of a skeletal disease or joint disease from disease-related information of a prediction target individual.　The disease onset risk prediction device according to the present disclosure comprises an information acquisition unit, a prediction unit, and an output unit, wherein: the information acquisition unit acquires disease-related information of a prediction target individual; the disease is a skeletal disease or a joint disease; the disease-related information includes at least one of information acquired through a medical checkup and information acquired by the prediction target individual; the prediction unit predicts the risk of onset of the disease in the prediction target individual from the disease-related information; and the output unit outputs the disease onset risk.

The present invention provides various methods for screening one or more compounds, suitably using non-invasive visual methods and neural networks for generating predicted fluorescence images of cells, to assess an effect of the compound on the cell, as well as to classify a compound or to determine an activity of a compound. Also provided are systems and methods for carrying out such assessments.

The invention discloses an application of intestinal flora metabolite salicylic acid as a predictive marker of Escherichia coli calf diarrhea. The obviously up-regulated metabolite salicylic acid is screened out from the diarrhea calf feces through a non-targeted metabonomics technology, and in a group of new independent samples, it is verified through an ELISA test that the salicylic acid concentration of the diarrhea calf feces is obviously higher than that of a healthy group. ROC curve analysis shows that the area under curve (AUC) of SA for predicting escherichia coli calf diarrhea is 0.8148, and the method has good prediction capability. The invention provides a non-invasive, cheap, rapid and high-specificity prediction method, can be used for early warning and auxiliary diagnosis of Escherichia coli calf diarrhea, and has important significance for guiding clinical precise medication and reducing the death rate of calves.

The present disclosure provides improved methods of treating endometrial cancer or ovarian cancer in a subject using levels of combinations of biomarkers as predictive markers for response to CDK2 inhibitors and combinations with CDK2 inhibitors.

The present invention discloses WTAP as a prognosis prediction marker for nasopharyngeal carcinoma, a detection primer and a kit, and relates to the field of molecular biotechnology of nasopharyngeal carcinoma. The present invention uses WTAP as a prognosis prediction marker for recurrent nasopharyngeal carcinoma, develops molecular primers for detecting WTAP expression, detects WTAP expression of recurrent nasopharyngeal carcinoma through molecular primers expressing WTAP, predicts the prognosis of this type, strengthens the post-treatment management or treatment of recurrent NPC patients with poor prognosis, and is expected to increase the 2-year survival of recurrent NPC patients with poor prognosis by 65% ​​and 55% respectively; the present invention is aimed at the population with relatively poor prognosis of recurrent NPC, and through the prediction of the prognosis of this type of patients by this kit, it is expected to significantly increase the 2-year or even 5-year survival rate of such patients.

The present disclosure provides improved methods of treating endometrial cancer or ovarian cancer in a subject using levels of combinations of biomarkers as predictive markers for response to CDK2 inhibitors and combinations with CDK2 inhibitors.

The present invention provides a gene detection method and kit for detecting tumor tissue gene variation and changes before and after synchronized radiotherapy to perform therapeutic response, recurrence and survival assessment of esophageal cancer patients. The invention develops an esophageal cancer NGS analysis kit. According to 402 variation sites containing 35 genes frequently occurring in esophageal squamous epithelial cell carcinoma tissue cells, 62 specific site variation of tissues before and after esophageal squamous epithelial cell carcinoma CCRT is analyzed, and it is expected that a new prediction marker can be found. The potential markers are combined into an esophageal cancer detection kit, and the kit has extremely high value for improving the prognosis of esophageal cancer.

The purpose of the present disclosure is to provide a disease onset risk prediction device for predicting the onset risk of an endocrine disease or a metabolic disease from disease-related information regarding a prediction subject.　A disease onset risk prediction device according to the present disclosure includes an information acquisition unit, a prediction unit and an output unit. The information acquisition unit acquires disease-related information regarding a prediction subject. The disease is an endocrine disease or a metabolic disease. The disease-related information contains at least one of information acquired by a health diagnosis and information acquired by the prediction subject. The prediction unit predicts a disease onset risk of the prediction subject from the disease-related information, and the output unit outputs the disease onset risk.

The invention relates to a construction method and application of a colorectal cancer liver metastasis promoting animal model of quail chicken enterococcus, and the construction method specifically comprises the following steps: constructing an in-situ starting colorectal cancer liver metastasis animal model, and carrying out isolated culture and identification on live bacteria in a liver metastasis focus of the model, so as to determine the quail chicken enterococcus as candidate bacteria; clinical sample analysis is further combined, and it is clear that the quail chicken enterococcus can play a role in the colorectal cancer liver metastasis process; and finally, further verifying the function of the quail chicken enterococcus SY2-1 with the preservation number of CCTCC (China Center For Type Culture Collection) NO: M20241929 by using two colorectal cancer liver metastasis models. The experiment result shows that the abundance and the detection positive rate of the quail chicken enterococcus in a clinical sample in the colorectal cancer liver metastasis focus of a patient are obviously higher than those of normal liver tissues, which indicates that the quail chicken enterococcus has the potential of serving as a predictive marker for occurrence and development of the colorectal cancer liver metastasis and serving as a biological intervention target of the colorectal cancer liver metastasis; and the enterococcus quail chicken SY2-1 can promote the construction of a colorectal cancer liver metastasis animal model.

The purpose of the present disclosure is to provide a disease onset risk prediction device for predicting an onset risk of a heart disease or a vascular system disease from disease-related information of a target to be predicted.　A disease onset risk prediction device according to the present disclosure includes an information acquisition unit, a prediction unit, and an output unit. The information acquisition unit acquires disease-related information of a target to be predicted. The disease is a heart disease or a vascular system disease. The disease-related information includes at least one of information acquired from a medical examination and information acquired from the target to be predicted. The prediction unit predicts a disease onset risk of the target to be predicted from the disease-related information. The output unit outputs the disease onset risk.

The present invention relates to the use of soluble CD27 as a biomarker to predict response to immune checkpoint inhibitor treatment. The inventors have collaborated with two queues of patients and have identified a soluble marker CD27 present in the plasma of renal cell carcinoma patients, the pre-treatment concentration of which can predict a response against PD-1 / PD-L1. The marker is more like a predictive marker of response to anti-PD-1 / PD-L1 therapy, rather than as a prognostic marker. In fact, it is independent of a better survival rate of metastatic renal cell carcinoma patients receiving treatment with anti-angiogenic agents. The markers are not associated with conventional clinical severity markers that classify metastatic kidney cancer patients.

Methods for levels of evidence-based categorization of tumor profiling results are described. The methods may comprise, for example, receiving tumor profiling results for a tumor derived from a subject; determining if a genomic alteration identified in the tumor profiling results is associated with an approved companion diagnostic finding; determining if the genomic alteration identified in the tumor profiling results is listed as a predictive marker of drug sensitivity or drug resistance for a given tumor type in at least one applicable guideline document; and reporting the genomic alteration as: (i) a Level 1 genomic alteration if the genomic alteration is associated with an approved companion diagnostic finding, or (ii) a Level 2 genomic alteration if the genomic alteration is listed as a predictive marker, or (iii) a Level 3 genomic alteration if the genomic alteration is not listed as a predictive marker.

The invention discloses a predictive marker as well as a related product and application thereof, and relates to the field of tumor diagnosis. The invention finds that WNT5A can be used as a marker of any one or more of disease risk, prognosis risk, disease progress, treatment effect, residual focus and metastatic focus of squamous-cell carcinoma, is beneficial to accurate diagnosis and treatment of squamous-cell carcinoma, and accelerates the research and development of new drugs.

The object of the present invention is the use of glycosphingolipid biosynthesis inhibitors for the treatment of tumors that are dependent on the oncogene GOLPH3 as well as on two oncogenes similar to GOLPH3 (GOLPH3-L and LCS, which form a GOLPH3 cluster with GOLPH3). Another object of the invention is the use of GOLPH3 genomic amplification detection as a predictive marker for identifying tumors responsive to said inhibitor.

The invention belongs to the technical field of biological medicine, and discloses application of a CRM1-PROM2 signal axis inhibitor in preparation of a gastric cancer cell ferroptosis inducer sensitizer, an anti-gastric cancer drug and a predictive marker. In the application provided by the invention, the CRM1-PROM2 signal axis is destroyed or inhibited by the CRM1-PROM2 signal axis inhibitor, so that the level of PROM2 in gastric cancer cytoplasm can be reduced, and then downstream KEAP1 / NRF2, FPN iron ion efflux and other ferroptosis resistance related signal axes are interfered, so that the ferroptosis sensitivity of gastric cancer cells is improved, and the treatment effect of the ferroptosis inducer on gastric cancer is enhanced; and the inhibitor shows certain targeting property in the aspect of enhancing the treatment effect of the ferroptosis inducer on the gastric cancer, and has important significance in realizing accurate diagnosis and treatment of the gastric cancer.

The invention particularly discloses a predictive marker for treating acute myelogenous leukemia on double-negative T cells, and relates to the technical field of biological medicines. The CD96 can be used as an intervention target point insensitive to DNT treatment of the AML patient, the killing effect of DNT on primary cells of the AML patient can be enhanced by specifically knocking out the CD96 or combining the CD96 with a CD96 specific blocking agent Nelistotug, and the insensitivity of DNT treatment of the AML patient is improved.